Then the Fed began its tapering talk.
With the potential of rising interest rates on the table, investors have shunned high dividend paying sectors and shares of REITs have plunged in wake of the Fed�� news. Yet, given the commercial real estate sectors long term history of outperformance, investors looking for bargains may want to scoop up shares of operators of shopping plazas, office buildings and hospitals.
SEE: The REIT Way
Better Valuations
After reaching a six-year high set on May 21, 2013, REITs have plunged about 14.75% since the Federal Reserve provided an update regarding its plans for future bond purchases. However, investors may not want to cast off their commercial real estate holdings just yet in the face of the Fed�� taper talk. That�� because REITs continue to offer plenty of portfolio benefits- and time to buy hasn�� been better.
Best Regional Bank Stocks To Watch For 2015: Henry Schein Inc. (HSIC)
Henry Schein, Inc. distributes healthcare products and services primarily to office-based healthcare practitioners. It operates in two segments, Healthcare Distribution and Technology. The Healthcare Distribution segment offers consumable dental products, dental laboratory products, and small equipment, including X-ray products, infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, and abrasives; and large dental equipment comprising dental chairs, delivery units and lights, X-ray equipment, equipment repair, and high-tech equipment. It also provides medical products, including branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, and vitamins; and animal health products, such as branded and generic pharmaceuticals, surgical and consumable products and services, and equipment. The Technology segment offers softwar e and related products, and value-added products that primarily include practice management software systems for dental and medical practitioners, and animal health clinics. Its services also consist of financial services and continuing education services for practitioners. Henry Schein, Inc. primarily serves dental practitioners and laboratories, physician practices, and animal health clinics, as well as government and other institutions. It operates in the United States, Australia, Austria, Belgium, Canada, China, the Czech Republic, France, Germany, Hong Kong, Ireland, Israel, Italy, Luxembourg, the Netherlands, New Zealand, Portugal, Slovakia, Spain, Switzerland, and the United Kingdom. The company was founded in 1932 and is headquartered in Melville, New York.
Advisors' Opinion:- [By Charles Mizrahi]
Several stocks in our portfolio will benefit from this trend: Drugstore chain Walgreens (WAG), healthcare products distributor Henry Schein (HSIC), and pharmaceutical maker AstraZeneca (AZN)
- [By John Bonnanzio]
The fund�� top holdings are Telsa, Henry Schein (HSIC), United Rentals (URI), Gartner (IT) and Kansas City Southern (KSU).
The fund also has some exposure to pricey biotech. Even so, this is hardly a shoot-the-lights-out growth fund as volatility is below all his mid-cap peers. To that end, this trade actually tempers risk while increasing growth exposure.
Top 10 Long Term Companies To Invest In 2014: Lonestar Resources Ltd (LNR)
Lonestar Resources Limited is an Australia-based independent oil and gas company involved in exploration, production, and acquisition of oil and gas reserves in the United States. The Company�� operations are focused onshore with primary activity in the Fort Worth Basin (Barnett Shale), Eagle Ford Shale, and the Williston Basin in Montana. The Company is active in sourcing other assets in producing areas. The Company�� Eagle Ford Shale portfolio comprises three separate assets: Beall Ranch, Asherton and Gonzo. The Company�� operations in the Williston Basin are focused on the Roosevelt County, Montana. The Company owns and operates a single lease in the Barnett Shale, a gas producing basin in North Texas. On January 2, 2013, the Company acquired Ecofin Energy Resources plc. In August 2013, the Company announced that it has sold its producing assets outside the state of Texas for its Louisiana assets and for its Oklahoma assets. Advisors' Opinion:- [By Eric Lam]
Linamar Corp. (LNR) soared 14 percent to a record C$40.72 for the biggest gain in the S&P/TSX. The Guelph, Ontario-based auto parts maker reported third-quarter adjusted profit of 80 Canadian cents a share, topping analysts��projections for 66 cents.
Top 10 Long Term Companies To Invest In 2014: Spdr Kbw Regional Banking (KRE)
SPDR KBW Regional Banking ETF (the Fund), formerly KBW Regional Banking ETF, is a non-diversified investment company. The Fund seeks to replicate as closely as possible the performance of the KBW Regional Banking Index (the Index). The Fund has entered into an investment advisory agreement with SSgA Funds Management, Inc.
The Regional Banking Index is an equal weighted index of geographically diverse companies representing regional banking institutions listed on the United States stock markets. It is created and maintained by Keefe, Bruyette & Woods, Inc.
Advisors' Opinion:- [By L.A. Little]
A slightly different kind of set-up is exhibited by the SPDR S&P Regional Banking ETF (KRE) � which has exhibited a strong continuation move of a prior leg up with good volume and the break of multiple swing points on the same time frame.
- [By Fiona MacDonald]
The Kuwait SE Price Index rose for a sixth day, climbing 0.5 percent to 6,851.17 at the close. Kuwait Real Estate Co. (KRE) climbed to the highest level in a month. Agility (AGLTY) advanced 1.7 percent after winning a $190 million UN contract in Sudan�� Darfur region. The Bloomberg GCC 200 Index, which tracks the biggest 200 companies in the Gulf Cooperation Council, fell 0.1 percent.
- [By Charley Blaine]
The Financial Select Sector SPDR (NYSE: XLF) exchange-traded fund is up 4.86%, tops among ETFs that mimic the sectors of the S&P 500. The SPDR S&P Regional Banking ETF (NYSE: KRE) is up 7.1 percent this month.
Top 10 Long Term Companies To Invest In 2014: AXT Inc(AXTI)
AXT, Inc., together with its subsidiaries, designs, develops, manufactures, and distributes compound and single element semiconductor substrates for use in wireless communications, lighting display applications, fiber optic communications, and solar cell. It offers semi-insulating substrates made from gallium arsenide, which are used in power amplifiers and radio frequency integrated circuits of wireless handsets, direct broadcast televisions, high-performance transistors, and satellite communications applications. The company also provides semi-conducting substrates made from gallium arsenide that are used for applications in light emitting diodes, lasers, and optical couplers; substrates made from indium phosphide used in broadband and fiber optic communications; and substrates made from germanium used in satellite and terrestrial solar cells, and for optical applications. It manufactures its semiconductor substrates using its proprietary vertical gradient freeze technol ogy. In addition, the company, through its joint venture agreements, manufactures and sells gallium, arsenic, germanium, germanium dioxide, paralytic boron nitride crucibles, and boron oxide. AXT, Inc. sells its products through direct sales force in the United States, as well as through independent sales representatives in France, Germany, Japan, South Korea, Taiwan, and the United Kingdom. The company was formerly known as American Xtal Technology, Inc. and changed its name to AXT, Inc. in July 2000. AXT, Inc. was founded in 1986 and is headquartered in Fremont, California.
Advisors' Opinion:- [By Eric Volkman]
SciClone (NASDAQ: SCLN ) has a new man leading its finance team. The company announced that it hired Wilson Cheung to be its new CFO. Cheung is a longtime executive who most recently served as chief compliance officer, Asia Pacific, at digital marketing agency Velti, following a stint as that company's CFO. Before that, he was CFO and corporate secretary at AXT (NASDAQ: AXTI ) and served in various managerial positions in firms such as KPMG and Yahoo!
Top 10 Long Term Companies To Invest In 2014: Golden Valley Bank (GVYB)
Golden Valley Bank is owned and operated commercial bank serving the needs of individuals and businesses in northern California. The Bank provides personal services, such as checking and savings and IRAs. The Bank�� business includes checking, savings, commercial lending, online banking and eDeposit.
The Bank provides business owners; commercial developers and investors, and residential builders and developers. Golden Valley Bank's business online banking service provides account management, bill pay and transactions services.
Advisors' Opinion:- [By CRWE]
Today, GVYB remains (0.00%) +0.000 at $9.00 thus far (ref. google finance Delayed: 11:59AM EDT July 17, 2013).
Golden Valley Bank headquartered in Chico, California previously reported June 30, 2013 financials. The company also announced their $.05 per share second quarter cash dividend.
2nd Quarter 2013 Financial Highlights: Year to date net profit $683,911 compared to $514,030 year to date in 2012; Assets up $14.9 million to $136.7 million, or 12.2%, over the second quarter of 2012; Loans up $6.2 million to $89.5 million, or 7.4%, over the second quarter of 2012; Deposits up $14.6 million to $118.6 million, or 14%, over the second quarter of 2012
The results of the Gravity Survey will be released once they are available
Top 10 Long Term Companies To Invest In 2014: Alere Inc (ALR)
Alere Inc., incorporated on May 11, 2001, is a provider of point-of-care diagnostics and services. The Company's products and services help healthcare practitioners make treatment decisions and improve outcomes for individuals living with chronic disease. The Company's portfolio also includes a range of health information solutions that access to critical health data, provide clinical decision support, and facilitate performance reporting and analysis. The Company�� segment includes professional diagnostics, health information solutions and consumer diagnostics. The Company distributes its professional diagnostic products to hospitals, reference laboratories, physician offices and other point-of-care settings through an worldwide distribution networks. In February 2013, the Company acquired Epocal, Inc.
Professional Diagnostics
Professional diagnostics are generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals, laboratories and doctors' offices and, increasingly, patient self-testing, which the Company defines as testing or monitoring performed at home under the supervision of a medical professional. Professional diagnostic products provide for qualitative or quantitative analysis of patient samples for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. The point-of-care market for rapid diagnostic products includes all areas where a patient is assessed or diagnosed, including hospitals, laboratories, physician offices, specialized mobile clinics, emergency rooms, rapid-response laboratories and patient health screening locations.
The Company's Alere Cholestech LDX System is a point-of-care monitor of blood cholesterol and related lipids which is used to test patients at risk of, or suffering from, heart disease and related conditions. The Alere Cholestech LDX System makes it possible to provide ! a complete lipid profile with tests for total cholesterol, high-density lipoprotein cholesterol (HDL) and low-density lipoprotein cholesterol (LDL), triglycerides, and glucose. The Company's Alere INRatio System is an easy-to-use, hand-held blood coagulation monitoring system for use by patients and healthcare professionals in the management of warfarin, a commonly prescribed medication used to prevent blood clots. The Company also offers the epoc Blood Analysis System for bloods gas, electrolyte and metabolite testing, which is manufactured by its recently acquired Epocal division. The epoc (enterprise point-of-care) platform is a point-of-care analysis system which provides Wireless bedside blood gas, electrolyte and metabolite measurement testing solutions and complements the Company's Alere Triage products in cardiology and emergency room settings.
The Company develops and markets a range of point-of-care tests for influenza A/B, RSV, strep throat, pneumonia, C. difficile, infectious mononucleosis, HIV, herpes simplex virus (HSV-2), hepatitis C (HCV), hepatitis B (HBV), malaria, lyme disease, Chlamydia, H. pylori, rubella and other infectious diseases. The Company's tests for infectious disease are sold under brand names that include Alere, Alere Determine, Acceava, BinaxNOW, Clearview, DoubleCheckGold, Panbio, SD, TECHLAB and Alere TestPack. In addition to point-of-care products, the Company also offers a line of indirect fluorescent antibody, or IFA, assays for over 20 viral, bacterial and autoimmune diseases, a full line of serology diagnostic products covering a range of disease categories and over 50 enzyme-linked immunosorbent assay (ELISA), tests for a range of infectious and autoimmune diseases, as well as a full line of automated instrumentation for processing ELISA tests.
The Company offers laboratory-based testing services throughout Europe under the name Alere Toxicology, formerly Concateno, and in the United States under the names Alere Toxicology Services, or! Alere To! xicology, and Redwood Toxicology Laboratory, or Redwood. The Company offers point-of-care diabetes products, including its Afinion Analyzer System and its NycoCard System. The Company's Alere Connect products include HealthPAL and HealthCOM.
Health Information Solutions
The Company's health information solutions are designed to provide physicians with actionable data that allows them to make more decisions in real time, deliver quality care, and put the individuals they treat on a pathway to better health. The Company offers a range of software-based analytics, clinical decision support tools, and accountable cares programs that enable healthcare providers to initiate earlier interventions, personalize treatment plans, lower costs by reducing hospital readmissions, and measure improvements in outcomes at both a patient and population level. With this range of scalable solutions, the Company is able to support healthcare practitioners in the transition to accountable care, as well as in meeting the new pay-for-performance guidelines set by the Centers for Medicare & Medicaid Services (CMS).
The Company's Women's and Children's Health division delivers a range of obstetrical care services that range from risk assessments focused on identifying women who may experience pregnancy complications to a neonatal program that supports early infant care management. The Company offers home-based obstetrical monitoring for pregnant women with medical or pregnancy-related problems that could puts their health or the health of their babies at risk. The Company also delivers telephonic and home-based nursing services that support improved clinical outcomes. The Company offers a suite of integrated wellness programs and resources that is designed to reduce participant health risks and healthcare-related costs. The Company's wellness programs include screening for risk factors associated with chronic disease, particularly tobacco use, poor nutrition, physical inactivity, and chron! ic stress! .
The Company offers services designed to support anticoagulation management for patients who takes warfarin to control their risk for stroke and clotting disorders. Alere Home Monitoring, the Company's patient self-testing business, assists patients in acquiring home INR monitors and with insurance coverage determinations and provides physicians with a comprehensive model that allows them to incorporate patient self-testing into their practices.
Consumer Diagnostics
The Company's consumer diagnostic products consist of the Company's First Check brand of over-the-counter drug tests for at-home testing for up to seven illicit drugs and five prescription drugs, as well as First Check brand over-the-counter tests for cholesterol monitoring. The Company also sells Balance Activ Vaginal Gel directly to consumers and healthcare professionals for the treatment of bacterial vaginosis without antibiotics.
The Company competes with Abbott, Siemens, Beckman Coulter, Johnson & Johnson, Roche, Abaxis Medical Diagnostics, International Technidyne Corporation, INOVA Diagnostics, DiaSorin, Diamedx and Qiagen.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Alere (NYSE: ALR ) , whose recent revenue and earnings are plotted below.
Top 10 Long Term Companies To Invest In 2014: CombiMatrix Corporation(CBMX)
CombiMatrix Corporation, a molecular diagnostics company, operates primarily in the fields of genetic analysis and molecular diagnostics in the United States. The company, through its wholly owned subsidiary, CombiMatrix Diagnostics, operates a diagnostics reference laboratory that provides DNA-based clinical diagnostic testing services to physicians, hospitals, and other laboratories in two primary areas, including prenatal and postnatal developmental disorders, and oncology. It offers a suite of developmental disorder array tests on the prenatal and postnatal application of array-comparative genomic hybridization in diagnosing genomic syndromes associated with developmental delays, autism spectrum disorders, dysmorphic features, and/or birth defects. The company also provides DNAarray?Heme Profile test to address various common hematological malignancies, including chronic lymphocytic leukemia; DNAarray?HER2 PRO test for breast cancer; and DNAarray?Tumor Profile test for the analysis of solid tumors, including breast, colon, lung, prostate, and brain tumors. In addition, it focuses on developing a series of drug compounds to address various oncology-related diseases. CombiMatrix Corporation was founded in 1995 and is based in Irvine, California.
Advisors' Opinion:- [By Bryan Murphy]
Looking for a couple of long (bullish) trading ideas on a day when the market is dragging pretty much everything lower? There are two names that fit the bill...CombiMatrix Corp. (NASDAQ:CBMX) and Banro Corporation (NYSEMKT:BAA). CBMX is an "almost" small cap stock that deserves a place on your watchlist while we wait for it to do one more thing. Meanwhile, BAA is something worth going ahead and taking a swing on now, not despite the market's tumble, but because of it.
- [By Wallace Witkowski]
Also, shares of Combimatrix Corp. (CBMX) rose 7.5% to $2.73 in moderate volume late Friday following a Securities and Exchange Commission filing showing Longwood Capital Partners acquired a 5.1% stake in the microcap molecular diagnostics company.
- [By Roberto Pedone]
One stock that's starting to trend within range of triggering a near-term breakout trade is CombiMatrix (CBMX), which operates a diagnostics reference laboratory that provides DNA-based clinical diagnostic testing services to physicians, hospitals, clinics and other laboratories in the areas of prenatal and postnatal development disorders, and hematology/oncology genomics. This stock hasn't done much over the last three months, with shares up by just 1.4%.
If you take a look at the chart for CombiMatrix, you'll notice that this stock has been uptrending over the last few weeks, with shares moving higher from its low of $2.14 to its recent high of $2.90 a share. During that move, shares of CBMX have been making mostly higher lows and higher highs, which is bullish technical price action. That uptrend has now pushed shares of CBMX within range of triggering a near-term breakout trade.
Traders should now look for long-biased trades in CBMX if it manages to break out above some near-term overhead resistance levels at $2.90 to $2.92 a share, and then once it clears its 200-day moving average at $2.96 to more near-term overhead resistance at $3.20 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 823,656 shares. If that breakout triggers soon, then CBMX will set up to re-test or possibly take out its next major overhead resistance levels at $3.70 to $4.44 a share.
Traders can look to buy CBMX off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average at $2.57 a share or just below more support at $2.20 to $2.14 a share. One can also buy CBMX off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
No comments:
Post a Comment